AstraZeneca PLC (NASDAQ:AZN) Holdings Lifted by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,978 shares of the company’s stock after acquiring an additional 3,359 shares during the period. Oppenheimer Asset Management Inc.’s holdings in AstraZeneca were worth $7,166,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC boosted its position in shares of AstraZeneca by 19.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after purchasing an additional 138 shares during the period. Carnegie Investment Counsel increased its stake in AstraZeneca by 0.8% in the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares in the last quarter. Crumly & Associates Inc. raised its holdings in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its stake in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Down 0.4 %

AstraZeneca stock opened at $65.04 on Friday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 0.93. The firm has a market cap of $201.66 billion, a PE ratio of 31.12, a P/E/G ratio of 1.21 and a beta of 0.47. The firm’s 50 day moving average price is $75.79 and its two-hundred day moving average price is $78.38.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the business posted $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, research analysts predict that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen boosted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.